City of Hope | Strategic Alliance Partners

January 17, 2018

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.

January 16, 2018

Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer.

January 08, 2018

Jae Y. Kim, MD, discusses developments with checkpoint inhibition in patients with resectable NSCLC.

January 05, 2018

Ravi Salgia, MD, PhD, discusses the evolution and current state of biomarker testing in the field of NSCLC.

January 02, 2018

Loretta Erhunmwunsee, MD, discusses the racial and socioeconomic disparities in lung cancer trials

December 13, 2017

City of Hope announced that it has appointed Michael A. Caligiuri, M.D., in a new executive leadership role as president of City of Hope National Medical Center and physician-in-chief.

November 17, 2017

Jonathan N. Warner, MD, reconstructive urologist, City of Hope, discusses the future of surgery for patients with prostate cancer.

November 14, 2017

Sumanta K. Pal, MD, discusses advancements in prostate cancer, bladder cancer, and promising results in kidney cancer.

September 19, 2017

Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.

March 24, 2017

City of Hope physician Arti Hurria knows what it is like to be a young faculty member balancing life as a doctor, researcher and parent.

February 17, 2017

Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses next steps for a phase I/II study of brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) in patients with relapsed or refractory Hodgkin lymphoma.

February 02, 2017

Jun Gong, MD, fellow, City of Hope, discusses adverse events (AEs) associated with TKI/VEGF-directed therapy for patients with metastatic renal cell carcinoma (RCC).

January 24, 2017

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the potential with immunotherapy in the preoperative setting for patients with renal cell carcinoma.

January 19, 2017

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses combination treatments in ovarian cancer.

December 17, 2016

Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, discusses the necessary steps toward determining optimal sequencing of treatments for patients with metastatic castration-resistant prostate cancer.

December 01, 2016

The treatment landscape of renal cell carcinoma is changing at a remarkably fast pace.

November 04, 2016

Bertram Yuh, MD, an assistant clinical professor of Urologic Oncology and a urologic oncology surgeon at City of Hope, compares the outcomes with surgery and radiation treatment in patients with localized prostate cancer. Yuh shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

November 03, 2016

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the challenges with sequencing the therapies available for patients with renal cell carcinoma (RCC). Pal shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

November 01, 2016

Clayton S. Lau, MD, director, Urologic Oncology, director, Robotic Surgery, Prostate Cancer Surgery, interim chair of Urology, City of Hope, discusses the controversies surrounding prostate cancer screening. Lau spoke on this in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

November 01, 2016

Surgery and radiation therapy are standard treatment options for localized prostate cancer, but are not comparative to one another.